Journal of Experimental & Clinical Cancer Research (Jul 2019)

Targeting mutant p53 in cancer: the latest insights

  • Silvia Di Agostino,
  • Giulia Fontemaggi,
  • Sabrina Strano,
  • Giovanni Blandino,
  • Gabriella D’Orazi

DOI
https://doi.org/10.1186/s13046-019-1302-0
Journal volume & issue
Vol. 38, no. 1
pp. 1 – 3

Abstract

Read online

Abstract This commentary wishes to highlight the latest discoveries in the mutant p53 field that have been discussed in the 8th p53 Mutant Workshop 2019, held in Lyon. TP53 mutant (mutp53) proteins are involved in the pathogenesis of most human cancers. Mutp53 proteins not only lose wild-typ53 function but, in some circumstances, may acquire novel oncogenic functions, namely gain-of-function (GOF), which lead to aberrant cell proliferation, chemoresistance, disruption of tissue architecture, migration, invasion and metastasis. Decoding the TP53 mutational spectrum and mutp53 interaction with additional transcription factors will therefore help to developing and testing novel and hopefully more efficient combinatorial therapeutic approaches.

Keywords